[go: up one dir, main page]

MA40254A - Polymorphes du selinexor - Google Patents

Polymorphes du selinexor

Info

Publication number
MA40254A
MA40254A MA040254A MA40254A MA40254A MA 40254 A MA40254 A MA 40254A MA 040254 A MA040254 A MA 040254A MA 40254 A MA40254 A MA 40254A MA 40254 A MA40254 A MA 40254A
Authority
MA
Morocco
Prior art keywords
selinexor
polymorphs
selinexor polymorphs
Prior art date
Application number
MA040254A
Other languages
English (en)
Other versions
MA40254B1 (fr
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MA40254A publication Critical patent/MA40254A/fr
Publication of MA40254B1 publication Critical patent/MA40254B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA40254A 2014-08-15 2015-08-14 Polymorphes du selinexor MA40254B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462038069P 2014-08-15 2014-08-15
PCT/US2015/045395 WO2016025904A1 (fr) 2014-08-15 2015-08-14 Formes polymorphes de selinexor

Publications (2)

Publication Number Publication Date
MA40254A true MA40254A (fr) 2021-05-19
MA40254B1 MA40254B1 (fr) 2022-09-30

Family

ID=53969460

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40254A MA40254B1 (fr) 2014-08-15 2015-08-14 Polymorphes du selinexor

Country Status (18)

Country Link
US (6) US10519139B2 (fr)
EP (2) EP3180331B1 (fr)
JP (3) JP6777626B2 (fr)
KR (1) KR102608259B1 (fr)
CN (3) CN111484483B (fr)
AU (4) AU2015301484B2 (fr)
CA (1) CA2957266A1 (fr)
CO (1) CO2017001884A2 (fr)
DK (1) DK3180331T3 (fr)
EA (1) EA201790384A1 (fr)
ES (1) ES2926377T3 (fr)
IL (1) IL250328B (fr)
MA (1) MA40254B1 (fr)
MX (2) MX388170B (fr)
SG (2) SG11201700789SA (fr)
UA (1) UA123535C2 (fr)
WO (1) WO2016025904A1 (fr)
ZA (1) ZA201700880B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3010892T3 (en) 2013-06-21 2019-04-15 Karyopharm Therapeutics Inc 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF
KR102608259B1 (ko) * 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10993943B2 (en) 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2019232724A1 (fr) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Composés en tant que modulateurs de transport nucléaire et leurs utilisations
WO2020072008A1 (fr) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Nouvelles dispersions solides de sélinexor
BR112021016762A2 (pt) * 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor
MX2021013211A (es) * 2019-05-01 2022-03-11 Karyopharm Therapeutics Inc Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
US20220218725A1 (en) * 2019-05-16 2022-07-14 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3808742A1 (fr) 2019-10-16 2021-04-21 Sandoz AG Polymorphe de selinexor
WO2022087218A1 (fr) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Forme cristalline de sélinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2023122014A1 (fr) * 2021-12-20 2023-06-29 Raytheon Technologies Corporation Amélioration de particules de composites à matrice céramique, son procédé de fabrication et articles la comprenant
CN116675677B (zh) * 2023-08-02 2023-09-26 中国林业科学研究院林产化学工业研究所 一种c8漆酚衍生物及其制备方法和应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
EP1671966A1 (fr) 1996-04-04 2006-06-21 Shionogi & Co., Ltd. Intermédiaires pour des dérivés de céphème
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
ATE244219T1 (de) 1996-04-25 2003-07-15 Nissan Chemical Ind Ltd Ethylenderivate und pestizide
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (fr) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP2083005A1 (fr) 2000-09-29 2009-07-29 TopoTarget UK Limited Composés d'acide carbamique comportant une liaison d'amide en tant qu'inhibiteurs HDAC
CA2465978C (fr) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibiteurs de l'histone-deacetylase
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
ZA200503967B (en) * 2002-11-01 2006-11-29 Takeda Pharmaceutical Agent for preventing or treating neuropathy
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
CA2512886A1 (fr) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
CN101014595A (zh) 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
WO2006019020A1 (fr) 2004-08-16 2006-02-23 Sankyo Company, Limited Urées de substitution
JPWO2006088246A1 (ja) 2005-02-18 2008-07-10 武田薬品工業株式会社 Ｇｐｒ３４受容体機能調節剤
TWI330639B (en) 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
JP5554988B2 (ja) 2006-04-07 2014-07-23 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
JP5290749B2 (ja) 2006-04-18 2013-09-18 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体δの活性化剤
WO2007147336A1 (fr) 2006-06-13 2007-12-27 Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences Composés non nucléosidiques hétérocycliques, leur préparation, compositions pharmaceutiques, et leur utilisation en tant qu'agents antiviraux
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
EP2090570B1 (fr) 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Dérivé d'imidazole
EP1939180A1 (fr) 2006-12-20 2008-07-02 sanofi-aventis Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale
EP1942104A1 (fr) 2006-12-20 2008-07-09 sanofi-aventis Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (fr) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
AU2010271205A1 (en) 2009-07-09 2012-02-09 Moko Therapeutics Llc. Method of wound healing and scar modulation
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
CA2824808A1 (fr) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Modulateurs du transport nucleaire contenant des olefines et leurs utilisations
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
WO2013019561A1 (fr) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2013020024A2 (fr) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Composés de maléimide et méthodes de traitement
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
US10202366B2 (en) * 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3010892T3 (en) 2013-06-21 2019-04-15 Karyopharm Therapeutics Inc 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF
WO2014205393A1 (fr) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
US11567063B2 (en) * 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
CN107209187B (zh) 2014-07-11 2021-04-20 国立健康与医学研究所 用于诊断血液癌症的方法
AU2015296322B2 (en) * 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US10777299B2 (en) 2015-08-28 2020-09-15 The Trustees Of Columbia University In The City Of New York Systems and methods for matching oncology signatures
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) * 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
US10993943B2 (en) * 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation
CN106831731B (zh) 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2020198606A1 (fr) 2019-03-27 2020-10-01 Karyopharm Therapeutics Inc. Biomarqueurs du selinexor
EP3808742A1 (fr) 2019-10-16 2021-04-21 Sandoz AG Polymorphe de selinexor
WO2021111103A1 (fr) 2019-12-06 2021-06-10 Bae Systems Plc Source lumineuse
WO2022087218A1 (fr) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Forme cristalline de sélinexor

Also Published As

Publication number Publication date
EP3180331A1 (fr) 2017-06-21
EA201790384A1 (ru) 2017-08-31
DK3180331T3 (da) 2022-09-12
AU2020203246A1 (en) 2020-06-04
MA40254B1 (fr) 2022-09-30
US11746102B2 (en) 2023-09-05
CN111481553A (zh) 2020-08-04
AU2015301484B2 (en) 2020-02-20
EP3180331B1 (fr) 2022-06-08
CN111484483A (zh) 2020-08-04
UA123535C2 (uk) 2021-04-21
ZA201700880B (en) 2020-01-29
SG10201808624VA (en) 2018-11-29
NZ728850A (en) 2024-03-22
US10519139B2 (en) 2019-12-31
SG11201700789SA (en) 2017-02-27
EP4112615A1 (fr) 2023-01-04
KR20170043561A (ko) 2017-04-21
AU2015301484A1 (en) 2017-03-02
CA2957266A1 (fr) 2016-02-18
JP2017527549A (ja) 2017-09-21
KR102608259B1 (ko) 2023-11-29
US20180215733A1 (en) 2018-08-02
JP2023052622A (ja) 2023-04-11
ES2926377T3 (es) 2022-10-25
WO2016025904A1 (fr) 2016-02-18
MX2021014128A (es) 2022-01-04
CN111484483B (zh) 2023-05-26
AU2020203246B2 (en) 2021-09-16
AU2024202835A1 (en) 2024-05-23
US20200283419A1 (en) 2020-09-10
JP7558310B2 (ja) 2024-09-30
AU2021286266A1 (en) 2022-01-06
CN107072992B (zh) 2020-03-10
JP2020143144A (ja) 2020-09-10
MX388170B (es) 2025-03-19
US20220135545A1 (en) 2022-05-05
JP7218323B2 (ja) 2023-02-06
CN111481553B (zh) 2023-09-01
MX2017002013A (es) 2017-05-12
US11807629B2 (en) 2023-11-07
IL250328A0 (en) 2017-03-30
JP6777626B2 (ja) 2020-10-28
CO2017001884A2 (es) 2017-07-19
US11753401B2 (en) 2023-09-12
CN107072992A (zh) 2017-08-18
US20230242516A1 (en) 2023-08-03
AU2021286266B2 (en) 2024-02-01
US11078190B2 (en) 2021-08-03
US12371420B2 (en) 2025-07-29
US20230242517A1 (en) 2023-08-03
IL250328B (en) 2022-05-01
US20240208943A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
FIC20240044I1 (fi) Odronekstamabi
FIC20230037I1 (fi) Glofitamabi
FIC20240035I1 (fi) Toferseeni
NL301275I2 (nl) zilucoplan
NO2022014I1 (no) Lonapegsomatropin
MA40254A (fr) Polymorphes du selinexor
LT3134402T (lt) 4-amino-imidazochinolino junginiai
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (fr) N-glycosylation
DK3183340T3 (da) Termolabile exonukleaser
EP4011484C0 (fr) Anhydrase carbonique de thermovibrio ammonificans
DE112015001664A5 (de) Betätigungsaktuator
FR3025617B1 (fr) Architecture bi-voies
DE112015005041A5 (de) Gargerätevorrichtung
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
BR112016027901A2 (pt) Compostos
DE112015001633A5 (de) Betätigungsaktuator